Johnson & Johnson
JNJ · NYSE
JNJ · NYSE
Johnson & Johnson sells prescription medicines and medical technologies to healthcare providers, hospitals, patients, and other healthcare systems globally. Its Innovative Medicine business develops and commercializes drugs, while MedTech sells products used in surgery, orthopedics, cardiovascular care, and other procedures. The company earns revenue from product sales across these businesses rather than from a single franchise, with STELARA among the products highlighted in the supplied coverage. J&J generated $94.2 billion of revenue and $26.8 billion of net income in fiscal 2025, versus $88.8 billion and $14.1 billion, respectively, in fiscal 2024.
JNJ fell $8.91, or 3.24%, from $275.23 to $266.32 across the supplied period. The decline was concentrated in the move to $269.12 on September 8, when volume rose to 8.1 million shares, and continued through September 11, when the stock closed at $265.58. It then recovered modestly to $266.32 on September 14, leaving it near the period low. The supplied evidence identifies no company-specific announcement, earnings update, analyst action, or market catalyst tied to these sessions, so the trading pattern appears to reflect selling pressure followed by a limited rebound rather than a documented fundamental repricing. No broader market context is provided to explain the move.
Johnson & Johnson rose 1.23%, from $265.85 to $269.12, despite a sharp late-week reversal. The stock climbed for three straight sessions, reaching $278.43 on September 3, before retreating to $275.23 on September 4 and giving back most of the advance in the September 8 session. The supplied evidence does not identify one dominant company-specific catalyst, although coverage highlighted JNJ’s device-business moves, a CE marking for a product, encouraging ACUVUE lens testing, and Phase 3 bipolar-mania data. Valuation commentary was mixed, with Simply Wall St. calling cash flow attractive but earnings fully priced and GuruFocus labeling the shares 38.3% overvalued. The September 8 decline was described as larger than the broader market’s dip.
JNJ rose $12.66, or 4.76%, from $265.77 to $278.43 over the week. The shares initially slipped 0.8% on Monday, then advanced for three consecutive sessions, gaining $5.34 on Tuesday, $4.02 on Wednesday and $3.22 on Thursday to finish at a record level. The most concrete company-specific catalyst was UBS assuming coverage with a Buy rating, while coverage also highlighted J&J’s participation in a broader healthcare-sector rally. ETF-related demand was another supportive factor, with JNJ among holdings associated with a notable iShares Russell 1000 Value ETF inflow. Broader conditions were constructive as crude oil prices and bond yields eased, helping stabilize stocks. No earnings release or new company guidance was reported during the week.
Johnson & Johnson fell $1.60, or 0.60%, from $267.37 to $265.77 over the week. The stock initially advanced, gaining to $273.04 on Monday and $273.14 on Tuesday, before reversing lower as Wednesday's close dropped to $270.00 and Thursday extended the decline to $265.77. The week's main company-specific catalyst was the FDA approval of Imaavy for patients aged 12 and older with warm autoimmune hemolytic anemia, making it the first treatment specifically indicated for the rare disease. The approval produced little lasting support, however, with J&J's shares giving back the early-week gains. Available evidence does not identify another company-specific event or broader-market driver explaining the late-week selling.
Johnson & Johnson rose $5.29, or 2.02%, from $262.08 to $267.37 over the week. The stock edged up Monday, then jumped 3.33% Tuesday and added 0.85% Wednesday as investors responded to product developments, including FDA 510(k) clearance for the MONARCH QUEST 3 robotic-bronchoscopy update and European approval of the TECVAYLI-daratumumab combination for relapsed or refractory multiple myeloma. JNJ gave back most of its midweek advance Thursday, falling 2.21% to $267.37. The supplied evidence does not identify a broader market catalyst or a company-specific explanation for Thursday’s reversal. Trading volume increased materially on the rally and remained elevated during the decline.
Johnson & Johnson rose 2.91%, from $254.41 to $261.81 over the supplied interval, advancing on four of five sessions and finishing at the period high. The move was steady rather than reversal-driven: shares edged up to $254.93 on Tuesday, gained 1.0% Wednesday, slipped $0.61 Thursday, then added $2.23 Friday and $2.57 on Monday. Monday volume increased to 8.99 million shares from 8.14 million at the period start. The supplied evidence does not establish a specific company announcement or analyst action as the decisive weekly catalyst. Instead, investor attention appears to have included broader discussion of a pharmaceutical recovery, J&J’s $5.5 billion talc settlement, leadership changes, and a cancer drug priority review.
Johnson & Johnson fell $11.80, or 4.42%, from $266.73 to $254.93 over the week. The decline was concentrated in the $9.71 drop on July 30, followed by a modest rebound on July 31, another $1.94 loss on August 3, and a $0.52 recovery on August 4. The supplied evidence does not identify a dated earnings release, guidance change, or other company-specific shock that explains the move. Instead, market context included a Dow milestone and an AI-driven technology sell-off, with JNJ cited among non-technology blue chips supported by earnings growth. Positive company themes—oncology growth, OTTAVA commercialization, and a reported JNJ-GSK deal—did not prevent the stock from weakening.
